Portfolio Strategy

Newbury’s portfolio is focused on the Nordic market and encompasses a broad range of therapeutic areas. The portfolio is built on a diversified model that includes both in-licensed products, for which Newbury serves as the marketing authorization holder, and products where Newbury has exclusive distribution rights and acts as the local representative for international partners.

This dual approach enables Newbury to combine regulatory and commercial expertise with a flexible partnership model that supports long-term growth. Through close collaboration with global pharmaceutical companies, Newbury ensures that innovative, high-quality treatments are made accessible to healthcare systems and patients throughout the region.

The current portfolio provides a robust foundation for sustained expansion and is expected to generate a steady flow of product launches in the coming years. These launches are driven by new in-licensing opportunities and strategic distribution agreements that continuously strengthen and broaden Newbury’s commercial offering.

Newbury actively evaluates opportunities that align with its strategic priorities – focusing on value creation, unmet medical needs, and long-term relevance within the Nordic healthcare landscape. By combining deep market knowledge with operational excellence in regulatory affairs, market access, supply chain management, and commercialization, Newbury is well positioned to continue its growth and serve as a trusted partner for pharmaceutical companies seeking to establish or expand their presence in the Nordic region.